Skip to content
Regeneration Center of Thailand Request Evaluation
Menu
Request Evaluation
HomeGranulocyte Colony-Stimulating Factor G-CSF Stimulation
Regenerative Healthcare

Granulocyte Colony-Stimulating Factor G-CSF Stimulation

A patient-focused guide to Granulocyte Colony-Stimulating Factor G-CSF Stimulation, with clinical context, evaluation considerations and supporting information.

Granulocyte colony-stimulating factor is also known as colony-stimulating factor 3 (CSF3), G-CSF or GCSF. It is a different protein from GM-CSF (granulocyte-macrophage colony-stimulating factor). G-CSF is a glycoprotein growth factor that the body makes in monocytes, fibroblasts and the endothelial cells lining blood vessels. It controls the production of neutrophils, a type of white blood cell, in the bone marrow, and it also strengthens some of their functions, such as engulfing bacteria.[1] As a medicine, it is used in two main ways: to protect people having chemotherapy from infection when their neutrophil count falls, and to move blood-forming stem cells out of the bone marrow into the blood so they can be collected for a transplant.[1]

Creating White Blood Cells

Video: Granulocyte Colony-Stimulating Factor G-CSF Stimulation

Chemotherapy often lowers the number of white blood cells, especially neutrophils (a low neutrophil count is called neutropenia), and that lowers resistance to infection. Filgrastim is approved in the United States to reduce infection, seen as fever with neutropenia, in people receiving chemotherapy for non-myeloid cancers; to speed neutrophil recovery after chemotherapy for acute myeloid leukaemia and after bone marrow transplantation; to treat severe chronic neutropenia; to mobilize blood stem cells for collection; and to improve survival after exposure to high doses of radiation.[1] Neutrophil counts typically start to rise 1 to 2 days after the first injection.[1] Not every chemotherapy course needs it: an American Society of Clinical Oncology guideline recommends preventive G-CSF when the risk of febrile neutropenia is about 20% or higher, or when a person’s age, medical history or disease puts them at high risk.[2]

Several G-CSF medicines are now in use:

Medicine How often it is given Used to mobilize stem cells?
Filgrastim and its biosimilars (in the US, the first was filgrastim-sndz in March 2015)[3] Daily injections Yes[1]
Lenograstim Daily injections Yes; used to mobilize stem cells in 3,928 unrelated donors at one German centre[4]
Pegfilgrastim and its biosimilars (the first US pegfilgrastim biosimilar was approved in June 2018)[3] Once per chemotherapy cycle; long-acting Not indicated for mobilization[5]
Eflapegrastim (US approval 2022) and efbemalenograstim alfa (US approval 2023)[6][7] Long-acting, once per chemotherapy cycle Not indicated for mobilization[6][7]

A biosimilar is highly similar to an approved original biological medicine and has no clinically meaningful differences from it.[8] In the US, five filgrastim biosimilars and eight pegfilgrastim biosimilars were listed by the FDA in October 2026.[3]

G-CSF Stimulation use in Stem Cell Therapies

Under normal conditions the great majority of blood-forming stem and progenitor cells stay in the bone marrow. Moving them into the blood (mobilization) is used to collect them for transplantation, and G-CSF is the prototypical mobilizing medicine.[9] They are held in their stem cell niche partly by a chemical signal, the chemokine SDF-1 (also called CXCL12), which binds the CXCR4 receptor on the stem cells.[10] G-CSF loosens this hold. In experiments in mice, G-CSF gradually lowered SDF-1 in the marrow, mostly because the enzyme neutrophil elastase broke it down, and antibodies that blocked SDF-1 or CXCR4 reduced the mobilization of both mouse and human stem cells.[11] In mice, G-CSF also strongly suppressed the bone-forming cells (osteoblasts) that are the main source of CXCL12 in the marrow.[12] For people whose stem cells do not mobilize well with G-CSF alone, the CXCR4 blocker plerixafor can be added to filgrastim; in the US it is approved for this use in people with non-Hodgkin lymphoma or multiple myeloma who are having an autologous transplant.[10]

Dosing and Timing of Collection

For collecting a patient’s own stem cells (autologous collection), the US label for filgrastim recommends 10 micrograms per kilogram of body weight a day, injected under the skin, for at least 4 days before the first collection and continued until the last. In the trials behind the label, filgrastim was given for 6 to 7 days, with collections on days 5, 6 and 7. Blood counts are checked, and filgrastim is stopped if the white cell count rises above 100,000 per cubic millimetre.[1] The cells are collected from the blood by leukapheresis, and are called peripheral blood progenitor cells or peripheral blood stem cells.[1]

Healthy donors, who give cells for another person’s transplant, are also mobilized with G-CSF; in one German centre, 3,928 unrelated donors received lenograstim at 7.5 micrograms per kilogram a day.[4] The US filgrastim label notes that mobilization in healthy donors is not one of its approved uses.[1]

Side Effects and Risks of G-CSF

The most common side effects during stem cell mobilization are bone pain, fever and headache.[1] In a prospective study of 2,408 unrelated donors given filgrastim, nearly all had bone pain and 1 in 4 had significant headache, nausea or citrate reactions from the collection; 6% had severe (grade III to IV) toxicity and 0.6% had serious, unexpected events. All donors recovered fully, and no late effects attributable to donation were found. Women and heavier donors had more side effects.[13]

Rare but serious risks listed in the prescribing information include:[1]

  • Splenic enlargement and rupture, including fatal cases. Pain in the upper left abdomen or the shoulder during treatment needs prompt medical assessment for an enlarged or ruptured spleen.
  • Sickle cell crisis, severe and sometimes fatal, in people with sickle cell disorders; the risks and benefits must be discussed before G-CSF is given to anyone with sickle cell disease.
  • Serious allergic reactions, including anaphylaxis. A history of serious allergic reaction to filgrastim or pegfilgrastim is the one listed contraindication.
  • Lung problems: acute respiratory distress syndrome, and bleeding into the lungs (alveolar haemorrhage with coughing up blood), which has been reported in healthy donors.
  • Capillary leak syndrome, with low blood pressure and swelling, which can be life-threatening if treatment is delayed.
  • Kidney inflammation (glomerulonephritis), inflammation of large blood vessels including the aorta, and skin vasculitis.
  • Very high white cell counts and low platelet counts, which is why blood counts are monitored.
  • Effects on cancer cells: the G-CSF receptor is found on some tumour cell lines, and mobilization can release tumour cells into the collected product. Myelodysplastic syndrome and acute myeloid leukaemia have been reported in people with breast and lung cancer given filgrastim with chemotherapy or radiotherapy.

Published Clinical Citations

[1] ^ Amgen Inc. NEUPOGEN (filgrastim) injection, for subcutaneous or intravenous use. US prescribing information, revised July 2026. DailyMed set ID 97cc73cc-b5b7-458a-a933-77b00523e193. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97cc73cc-b5b7-458a-a933-77b00523e193

[2] ^ Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology. 2015;33(28):3199-3212. https://doi.org/10.1200/JCO.2015.62.3488

[3] ^ US Food and Drug Administration. Biosimilar Product Information. Content current as of 28 October 2026. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information

[4] ^ Hölig K, Kramer M, Kroschinsky F, et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood. 2009;114(18):3757-3763. https://doi.org/10.1182/blood-2009-04-218651

[5] ^ Amgen Inc. NEULASTA (pegfilgrastim) injection, for subcutaneous use. US prescribing information. DailyMed set ID fdfe5d72-6b80-435a-afa4-c5d74dd852ce (published 19 October 2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fdfe5d72-6b80-435a-afa4-c5d74dd852ce

[6] ^ Spectrum Pharmaceuticals. ROLVEDON (eflapegrastim-xnst) injection. US prescribing information, initial US approval 2022. DailyMed set ID 6e436115-62e7-4729-aeb0-ff78ea685206. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e436115-62e7-4729-aeb0-ff78ea685206

[7] ^ Acrotech Biopharma. RYZNEUTA (efbemalenograstim alfa-vuxw) injection. US prescribing information, initial US approval 2023. DailyMed set ID 290ed754-758c-9cae-e063-6294a90ae68b. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=290ed754-758c-9cae-e063-6294a90ae68b

[8] ^ US Food and Drug Administration. Biosimilar Basics for Patients. Content current as of 1 August 2024. https://www.fda.gov/drugs/biosimilars/biosimilars-basics-patients

[9] ^ Greenbaum AM, Link DC. Mechanisms of G-CSF-mediated hematopoietic stem and progenitor mobilization. Leukemia. 2011;25(2):211-217. https://doi.org/10.1038/leu.2010.248

[10] ^ Sanofi-Aventis US. MOZOBIL (plerixafor) injection. US prescribing information, initial US approval 2008. DailyMed set ID 0ed08d2b-5051-46b2-aa37-1d6275bf9003. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ed08d2b-5051-46b2-aa37-1d6275bf9003

[11] ^ Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nature Immunology. 2002;3(7):687-694. https://doi.org/10.1038/ni813

[12] ^ Semerad CL, Christopher MJ, Liu F, et al. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood. 2005;106(9):3020-3027. https://doi.org/10.1182/blood-2004-01-0272

[13] ^ Pulsipher MA, Chitphakdithai P, Miller JP, et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood. 2009;113(15):3604-3611. https://doi.org/10.1182/blood-2008-08-175323